Justus Bingham: Board; VP, Drug Developmen
Biography
Justus Bingham has over 20 years of experience in the pharmaceutical industry. He specializes in clinical pharmacology, pharmacokinetics and pharmacometrics, with expertise in modeling and simulation. At CV Therapeutics, he managed PK/PD for the company’s pipeline in all development phases. Mr. Bingham has experience in both small and large molecule pharmaceutical research and development, having worked at Eli Lilly, CV Therapeutics, and Gilead.
Fourteen years ago, Mr. Bingham transitioned to consulting and long-term contracting. Initially his focus was on leveraging quantitative modeling and simulation to accelerate pharmaceutical development. He has developed new methodologies in statistical bootstrapping that are faster and more accurate than standard techniques. These methodologies can be widely used when processing time is a bottleneck. Mr. Bingham has served as a consultant at Genentech and Certara, providing his expertise to companies like Pfizer, Eli Lilly, Rosa, Navitas Pharma, Vitaeris, RRD International, Gilead, STC Biologics, BASF, Dexport, Kineta Inc., University of Illinois at Champaign-Urbana Supercomputing Center, Principal, and Deloitte Consulting. He has assisted clients with PK/PD analysis, clinical pharmacology, study design, modeling and simulation, regulatory matters, statistics, drug development strategy, and financial modeling. He has been involved in the development of more than 100 compounds across a wide range of therapeutic areas including cardiovascular, endocrinology, oncology, anti-viral, anti-infective, anti-inflammatory, and CNS. He has extensive experience in the design, analysis and reporting of clinical pharmacology studies, including population PK/PD, PK/PD modeling and simulation, and clinical trial simulation. He has been involved in the preparation of numerous regulatory submissions including INDs, NDAs, and BLAs.
In 2018, Mr. Bingham with Grant Hogeland co-founded Momentum Metrix, a company that provides bespoke pharmacometric analysis for pharmaceutical and biotech companies. He is currently the Executive Chairman of the company. Momentum Metrix also partners with several CROs to offer their services.
Since 2019, Mr. Bingham has co-founded or taken executive roles with multiple biotech and pharma companies. His focus is on using modeling and simulation with AI to speed up drug development.